Einar Osland Vik-Mo

  • Post doc., MD, PhD
  • +47 23071398

Identification and immuo-optic targeting of tumor stem cells in patients with glioblastoma

Central nervous system malignancies accounts for 1% of all adult cancers. The most common primary brain neoplasm is a glioma, which accounts for approximately half of all intracranial neoplasms. In patients with glioblastoma multiforme, the most malignant of gliomas, median survival has remained 9 to 12 months for decades.

The treatment of gliomas is based on surgical resection, but this is inadequate. The reason for this shortcoming has been hypothesized to be a result of tumour infiltration into healthy tissue, thus making it non resectable. Adjuvant radio- and chemotherapy may prolong the patients life, but eventually most patients relapse.

For nearly one hundred years, glia cells were thought to be the only dividing cells in the postnatal brain, thus, making them the candidates susceptible to malignant transformation. As the concept of neuronal stem cells emerges, the cellular antecedent of gliomas is being once again reviewed in the light of this new evidence. As stem cells already have the machinery necessary for self-renewal, fewer mutagenic events may be necessary for tumourigenic transformation than in differentiated cells. Neural stem cells also exhibit properties similar to tumour cells, i.e. high motility, diversity of progeny, robust proliferative potential, association with blood vessels and white-matter tracts and an immature expression profile.

Prospective isolation of tumour initiating cells is possible using tumour specific antigens. We are currently working on the isolation and characterization of such tumour initiating cells using primary cell cultures, both as floating neurosphere assays and adherent cultures, and combining this with FACS and MACS to prospectively isolate the putative tumour initiating cells.

 

Publications 2024

Blakstad H, Mendoza Mireles EE, Kierulf-Vieira KS, Singireddy D, Mdala I, Heggebø LC, Magelssen H, Sprauten M, Johannesen TB, Leske H, Niehusmann P, Skogen K, Helseth E, Emblem KE, Vik-Mo EO, Brandal P (2024)
The impact of cancer patient pathway on timing of radiotherapy and survival: a cohort study in glioblastoma patients
J Neurooncol, 169 (1), 137-145
DOI 10.1007/s11060-024-04709-z, PubMed 38762830

Halldorsson S, Nagymihaly RM, Patel A, Brandal P, Panagopoulos I, Leske H, Lund-Iversen M, Sahm F, Vik-Mo EO (2024)
Accurate and comprehensive evaluation of O6-methylguanine-DNA methyltransferase promoter methylation by nanopore sequencing
Neuropathol Appl Neurobiol, 50 (3), e12984
DOI 10.1111/nan.12984, PubMed 38783575

Karschnia P, Gerritsen JKW, Teske N, Cahill DP, Jakola AS, van den Bent M, Weller M, Schnell O, Vik-Mo EO, Thon N, Vincent AJPE, Kim MM, Reifenberger G, Chang SM, Hervey-Jumper SL, Berger MS, Tonn JC (2024)
The oncological role of resection in newly diagnosed diffuse adult-type glioma defined by the WHO 2021 classification: a Review by the RANO resect group
Lancet Oncol, 25 (9), e404-e419
DOI 10.1016/S1470-2045(24)00130-X, PubMed 39214112

Luque L, Skogen K, MacIntosh BJ, Emblem KE, Larsson C, Bouget D, Helland RH, Reinertsen I, Solheim O, Schellhorn T, Vardal J, Mireles EEM, Vik-Mo EO, Bjørnerud A (2024)
Standardized evaluation of the extent of resection in glioblastoma with automated early post-operative segmentation
Front Radiol, 4, 1357341
DOI 10.3389/fradi.2024.1357341, PubMed 38840717

Skaga E, Trewin-Nybråten CB, Niehusmann P, Johannesen TB, Marienhagen K, Oltedal L, Schipman S, Skjulsvik AJ, Solheim O, Solheim TS, Sundstrøm T, Vik-Mo EO, Petter Brandal, Ingebrigtsen T (2024)
Stable glioma incidence and increased patient survival over the past two decades in Norway: a nationwide registry-based cohort study
Acta Oncol, 63, 83-94
DOI 10.2340/1651-226X.2024.24970, PubMed 38501768

Publications 2023

Blakstad H, Mendoza Mireles EE, Heggebø LC, Magelssen H, Sprauten M, Johannesen TB, Vik-Mo EO, Leske H, Niehusmann P, Skogen K, Helseth E, Emblem KE, Brandal P (2023)
Incidence and outcome of pseudoprogression after radiation therapy in glioblastoma patients: A cohort study
Neurooncol Pract, 11 (1), 36-45
DOI 10.1093/nop/npad063, PubMed 38222046

Brynjulvsen M, Solli E, Walewska M, Zucknick M, Djirackor L, Langmoen IA, Mughal AA, Skaga E, Vik-Mo EO, Sandberg CJ (2023)
Functional and Molecular Heterogeneity in Glioma Stem Cells Derived from Multiregional Sampling
Cancers (Basel), 15 (24)
DOI 10.3390/cancers15245826, PubMed 38136371

Heggebø LC, Borgen IMH, Rylander H, Kiserud C, Nordenmark TH, Hellebust TP, Evensen ME, Gustavsson M, Ramberg C, Sprauten M, Magelssen H, Blakstad H, Moorthy J, Andersson K, Raunert I, Henry T, Moe C, Granlund C, Goplen D, Brekke J, Johannessen TA, Solheim TS, Marienhagen K, Humberset Ø, Bergström P et al. (2023)
Investigating survival, quality of life and cognition in PROton versus photon therapy for IDH-mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden
BMJ Open, 13 (3), e070071
DOI 10.1136/bmjopen-2022-070071, PubMed 36940951

Mendoza Mireles EE, Skaga E, Server A, Leske H, Brandal P, Helseth E, Rønning PA, Vik-Mo EO (2023)
The benefit of complete resection of contrast enhancing tumor in glioblastoma patients: A population-based study
Neurooncol Pract, 10 (6), 555-564
DOI 10.1093/nop/npad037, PubMed 38026582

Schipmann-Miletic S, Sivakanesan S, Rath DS, Brandal P, Vik-Mo E, Bjørås M, Solheim O, Ingebrigtsen T, Sund F, Bjerkvig R, Miletic H, Johannessen TA, Sundstrøm T (2023)
[Glioblastoma in adults]
Tidsskr Nor Laegeforen, 143 (2)
DOI 10.4045/tidsskr.22.0314, PubMed 36718891

Svensson SF, Halldórsson S, Latysheva A, Fuster-Garcia E, Hjørnevik T, Fraser-Green J, Birkeland Bugge RA, Grinband J, Holm S, Sinkus R, Vik-Mo EO, Emblem KE (2023)
MR elastography identifies regions of extracellular matrix reorganization associated with shorter survival in glioblastoma patients
Neurooncol Adv, 5 (1), vdad021
DOI 10.1093/noajnl/vdad021, PubMed 37066109

Winther RR, Skovlund E, Andreassen JS, Arvidsson L, Halvardson J, Solheim O, Bartek J, Kaasa S, Hjermstad MJ, Vik-Mo EO (2023)
Preoperative Prognostic Index for Patients with Brain Metastases-A Population-Based Multi-Centre Study
Cancers (Basel), 15 (12)
DOI 10.3390/cancers15123174, PubMed 37370784

Publications 2022

Skaga E, Kulesskiy E, Potdar S, Panagopoulos I, Micci F, Langmoen IA, Sandberg CJ, Vik-Mo EO (2022)
Functional temozolomide sensitivity testing of patient-specific glioblastoma stem cell cultures is predictive of clinical outcome
Transl Oncol, 26, 101535
DOI 10.1016/j.tranon.2022.101535, PubMed 36115076

Winther RR, Hjermstad MJ, Skovlund E, Aass N, Helseth E, Kaasa S, Yri OE, Vik-Mo EO (2022)
Surgery for brain metastases-impact of the extent of resection
Acta Neurochir (Wien), 164 (10), 2773-2780
DOI 10.1007/s00701-021-05104-7, PubMed 35080651

Publications 2021

Djirackor L, Halldorsson S, Niehusmann P, Leske H, Capper D, Kuschel LP, Pahnke J, Due-Tønnessen BJ, Langmoen IA, Sandberg CJ, Euskirchen P, Vik-Mo EO (2021)
Intraoperative DNA methylation classification of brain tumors impacts neurosurgical strategy
Neurooncol Adv, 3 (1), vdab149
DOI 10.1093/noajnl/vdab149, PubMed 34729487

Fløgstad Svensson S, Fuster-Garcia E, Latysheva A, Fraser-Green J, Nordhøy W, Isam Darwish O, Thokle Hovden I, Holm S, Vik-Mo EO, Sinkus R, Eeg Emblem K (2021)
Decreased tissue stiffness in glioblastoma by MR elastography is associated with increased cerebral blood flow
Eur J Radiol, 147, 110136
DOI 10.1016/j.ejrad.2021.110136, PubMed 35007982

Munkvold BKR, Solheim O, Bartek J, Corell A, de Dios E, Gulati S, Helseth E, Holmgren K, Jensdottir M, Lundborg M, Mireles EEM, Mahesparan R, Tveiten ØV, Milos P, Redebrandt HN, Pedersen LK, Ramm-Pettersen J, Sjöberg RL, Sjögren B, Sjåvik K, Smits A, Tomasevic G, Vecchio TG, Vik-Mo EO, Zetterling M et al. (2021)
Variations in the management of diffuse low-grade gliomas-A Scandinavian multicenter study
Neurooncol Pract, 8 (6), 706-717
DOI 10.1093/nop/npab054, PubMed 34777840

Skaga E, Skretteberg MA, Johannesen TB, Brandal P, Vik-Mo EO, Helseth E, Langmoen IA (2021)
Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply?
Neurooncol Adv, 3 (1), vdab008
DOI 10.1093/noajnl/vdab008, PubMed 33665615

Svensson SF, De Arcos J, Darwish OI, Fraser-Green J, Storås TH, Holm S, Vik-Mo EO, Sinkus R, Emblem KE (2021)
Robustness of MR Elastography in the Healthy Brain: Repeatability, Reliability, and Effect of Different Reconstruction Methods
J Magn Reson Imaging, 53 (5), 1510-1521
DOI 10.1002/jmri.27475, PubMed 33403750

Winther RR, Vik-Mo EO, Yri OE, Aass N, Kaasa S, Skovlund E, Helseth E, Hjermstad MJ (2021)
Surgery for brain metastases - real-world prognostic factors' association with survival
Acta Oncol, 60 (9), 1161-1168
DOI 10.1080/0284186X.2021.1930150, PubMed 34032547

Publications 2020

Digernes I, Nilsen LB, Grøvik E, Bjørnerud A, Løvland G, Vik-Mo E, Meling TR, Saxhaug C, Helland Å, Jacobsen KD, Geier O, Emblem KE (2020)
Noise dependency in vascular parameters from combined gradient-echo and spin-echo DSC MRI
Phys Med Biol, 65 (22), 225020
DOI 10.1088/1361-6560/abb71a, PubMed 33200748

Hovden IT, Geier OM, Digernes I, Fuster-Garcia E, Løvland G, Vik-Mo E, Meling TR, Emblem KE (2020)
The impact of EPI-based distortion correction of dynamic susceptibility contrast MRI on cerebral blood volume estimation in patients with glioblastoma
Eur J Radiol, 132, 109278
DOI 10.1016/j.ejrad.2020.109278, PubMed 33010685

Kierulf-Vieira KS, Sandberg CJ, Waaler J, Lund K, Skaga E, Saberniak BM, Panagopoulos I, Brandal P, Krauss S, Langmoen IA, Vik-Mo EO (2020)
A Small-Molecule Tankyrase Inhibitor Reduces Glioma Stem Cell Proliferation and Sphere Formation
Cancers (Basel), 12 (6)
DOI 10.3390/cancers12061630, PubMed 32575464

Latysheva A, Geier OM, Hope TR, Brunetti M, Micci F, Vik-Mo EO, Emblem KE, Server A (2020)
Diagnostic utility of Restriction Spectrum Imaging in the characterization of the peritumoral brain zone in glioblastoma: Analysis of overall and progression-free survival
Eur J Radiol, 132, 109289
DOI 10.1016/j.ejrad.2020.109289, PubMed 33002815

Publications 2019

Hvinden IC, Berg HE, Sachse D, Skaga E, Skottvoll FS, Lundanes E, Sandberg CJ, Vik-Mo EO, Rise F, Wilson SR (2019)
Nuclear Magnetic Resonance Spectroscopy to Identify Metabolite Biomarkers of Nonresponsiveness to Targeted Therapy in Glioblastoma Tumor Stem Cells
J Proteome Res, 18 (5), 2012-2020
DOI 10.1021/acs.jproteome.8b00801, PubMed 30964684

Latysheva A, Emblem KE, Brandal P, Vik-Mo EO, Pahnke J, Røysland K, Hald JK, Server A (2019)
Dynamic susceptibility contrast and diffusion MR imaging identify oligodendroglioma as defined by the 2016 WHO classification for brain tumors: histogram analysis approach
Neuroradiology, 61 (5), 545-555
DOI 10.1007/s00234-019-02173-5, PubMed 30712139

Skaga E, Kulesskiy E, Brynjulvsen M, Sandberg CJ, Potdar S, Langmoen IA, Laakso A, Gaál-Paavola E, Perola M, Wennerberg K, Vik-Mo EO (2019)
Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment
Clin Transl Med, 8 (1), 33
DOI 10.1186/s40169-019-0253-6, PubMed 31889236

Skaga E, Kulesskiy E, Fayzullin A, Sandberg CJ, Potdar S, Kyttälä A, Langmoen IA, Laakso A, Gaál-Paavola E, Perola M, Wennerberg K, Vik-Mo EO (2019)
Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma
BMC Cancer, 19 (1), 628
DOI 10.1186/s12885-019-5861-4, PubMed 31238897

Skaga E, Skaga IØ, Grieg Z, Sandberg CJ, Langmoen IA, Vik-Mo EO (2019)
The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy
J Cancer Res Clin Oncol, 145 (6), 1495-1507
DOI 10.1007/s00432-019-02920-4, PubMed 31028540

Publications 2018

Fayzullin A, Sandberg CJ, Spreadbury M, Saberniak BM, Grieg Z, Skaga E, Langmoen IA, Vik-Mo EO (2018)
Phenotypic and Expressional Heterogeneity in the Invasive Glioma Cells
Transl Oncol, 12 (1), 122-133
DOI 10.1016/j.tranon.2018.09.014, PubMed 30292065

Mughal AA, Zhang L, Fayzullin A, Server A, Li Y, Wu Y, Glass R, Meling T, Langmoen IA, Leergaard TB, Vik-Mo EO (2018)
Patterns of Invasive Growth in Malignant Gliomas-The Hippocampus Emerges as an Invasion-Spared Brain Region
Neoplasia, 20 (7), 643-656
DOI 10.1016/j.neo.2018.04.001, PubMed 29793116

Skottvoll FS, Berg HE, Bjørseth K, Lund K, Roos N, Bekhradnia S, Thiede B, Sandberg C, Vik-Mo EO, Roberg-Larsen H, Nyström B, Lundanes E, Wilson SR (2018)
Ultracentrifugation versus kit exosome isolation: nanoLC-MS and other tools reveal similar performance biomarkers, but also contaminations
Future Sci OA, 5 (1), FSO359
DOI 10.4155/fsoa-2018-0088, PubMed 30652024

Publications 2017

Digernes I, Bjørnerud A, Vatnehol SAS, Løvland G, Courivaud F, Vik-Mo E, Meling TR, Emblem KE (2017)
A theoretical framework for determining cerebral vascular function and heterogeneity from dynamic susceptibility contrast MRI
J Cereb Blood Flow Metab, 37 (6), 2237-2248
DOI 10.1177/0271678X17694187, PubMed 28273722

Publications 2016

Fayzullin A, Tuvnes FA, Skjellegrind HK, Behnan J, Mughal AA, Langmoen IA, Vik-Mo EO (2016)
Time-lapse phenotyping of invasive glioma cells ex vivo reveals subtype-specific movement patterns guided by tumor core signaling
Exp Cell Res, 349 (2), 199-213
DOI 10.1016/j.yexcr.2016.08.001, PubMed 27515001

Skjellegrind HK, Fayzullin A, Johnsen EO, Eide L, Langmoen IA, Moe MC, Vik-Mo EO (2016)
Short-Term Differentiation of Glioblastoma Stem Cells Induces Hypoxia Tolerance
Neurochem Res, 41 (7), 1545-58
DOI 10.1007/s11064-016-1868-2, PubMed 26915110

Publications 2015

Kierulf-Vieira KS, Sandberg CJ, Grieg Z, Günther CC, Langmoen IA, Vik-Mo EO (2015)
Wnt inhibition is dysregulated in gliomas and its re-establishment inhibits proliferation and tumor sphere formation
Exp Cell Res, 340 (1), 53-61
DOI 10.1016/j.yexcr.2015.12.010, PubMed 26712519

Mughal AA, Grieg Z, Skjellegrind H, Fayzullin A, Lamkhannat M, Joel M, Ahmed MS, Murrell W, Vik-Mo EO, Langmoen IA, Stangeland B (2015)
Knockdown of NAT12/NAA30 reduces tumorigenic features of glioblastoma-initiating cells
Mol Cancer, 14, 160
DOI 10.1186/s12943-015-0432-z, PubMed 26292663

Stangeland B, Mughal AA, Grieg Z, Sandberg CJ, Joel M, Nygård S, Meling T, Murrell W, Vik Mo EO, Langmoen IA (2015)
Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells
Oncotarget, 6 (28), 26192-215
DOI 10.18632/oncotarget.4613, PubMed 26295306

Publications 2014

Behnan J, Isakson P, Joel M, Cilio C, Langmoen IA, Vik-Mo EO, Badn W (2014)
Recruited brain tumor-derived mesenchymal stem cells contribute to brain tumor progression
Stem Cells, 32 (5), 1110-23
DOI 10.1002/stem.1614, PubMed 24302539

Kommedal Ø, Wilhelmsen MT, Skrede S, Meisal R, Jakovljev A, Gaustad P, Hermansen NO, Vik-Mo E, Solheim O, Ambur OH, Sæbø Ø, Høstmælingen CT, Helland C (2014)
Massive parallel sequencing provides new perspectives on bacterial brain abscesses
J Clin Microbiol, 52 (6), 1990-7
DOI 10.1128/JCM.00346-14, PubMed 24671797

Sandberg CJ, Vik-Mo EO, Behnan J, Helseth E, Langmoen IA (2014)
Transcriptional profiling of adult neural stem-like cells from the human brain
PLoS One, 9 (12), e114739
DOI 10.1371/journal.pone.0114739, PubMed 25514637

Vik-Mo EO, Krossnes BK, Stanisic M, Egge A, Holter E, Taubøll E, Heuser K, Lund CG (2014)
Reactivation of occult herpes simplex meningoencephalitis after temporal lobe resection for refractory epilepsy--a case report
Seizure, 23 (4), 321-3
DOI 10.1016/j.seizure.2014.01.010, PubMed 24521759

Publications 2013

Joel M, Sandberg CJ, Boulland JL, Vik-Mo EO, Langmoen IA, Glover JC (2013)
Inhibition of tumor formation and redirected differentiation of glioblastoma cells in a xenotypic embryonic environment
Dev Dyn, 242 (9), 1078-93
DOI 10.1002/dvdy.24001, PubMed 23780720

Murrell W, Palmero E, Bianco J, Stangeland B, Joel M, Paulson L, Thiede B, Grieg Z, Ramsnes I, Skjellegrind HK, Nygård S, Brandal P, Sandberg C, Vik-Mo E, Palmero S, Langmoen IA (2013)
Expansion of multipotent stem cells from the adult human brain
PLoS One, 8 (8), e71334
DOI 10.1371/journal.pone.0071334, PubMed 23967194

Sandberg CJ, Altschuler G, Jeong J, Strømme KK, Stangeland B, Murrell W, Grasmo-Wendler UH, Myklebost O, Helseth E, Vik-Mo EO, Hide W, Langmoen IA (2013)
Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt- signaling and a fingerprint associated with clinical outcome
Exp Cell Res, 319 (14), 2230-43
DOI 10.1016/j.yexcr.2013.06.004, PubMed 23791939

Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tønnesen P, Suso EM, Sæbøe-Larssen S, Sandberg C, Brinchmann JE, Helseth E, Rasmussen AM, Lote K, Aamdal S, Gaudernack G, Kvalheim G, Langmoen IA (2013)
Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
Cancer Immunol Immunother, 62 (9), 1499-509
DOI 10.1007/s00262-013-1453-3, PubMed 23817721

Publications 2012

Boulland JL, Leung DS, Thuen M, Vik-Mo E, Joel M, Perreault MC, Langmoen IA, Haraldseth O, Glover JC (2012)
Evaluation of intracellular labeling with micron-sized particles of iron oxide (MPIOs) as a general tool for in vitro and in vivo tracking of human stem and progenitor cells
Cell Transplant, 21 (8), 1743-59
DOI 10.3727/096368911X627598, PubMed 22490338

Fossdal G, Vik-Mo EO, Sandberg C, Varghese M, Kaarbø M, Telmo E, Langmoen IA, Murrell W (2012)
Aqp 9 and brain tumour stem cells
ScientificWorldJournal, 2012, 915176
DOI 10.1100/2012/915176, PubMed 22262958

Publications 2011

Vik-Mo EO (2011)
Propagation and characterization of stem like cells from brain tumors - establishment of a clinical protocol for immunotherapeutic targeting of tumor stem cells in glioblastomas
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 1145, 1 b. (flere pag.)
BIBSYS 11276729x, ISBN 978-82-8264-143-2

Vik-Mo EO, Sandberg C, Joel M, Stangeland B, Watanabe Y, Mackay-Sim A, Moe MC, Murrell W, Langmoen IA (2011)
A comparative study of the structural organization of spheres derived from the adult human subventricular zone and glioblastoma biopsies
Exp Cell Res, 317 (7), 1049-59
DOI 10.1016/j.yexcr.2010.12.022, PubMed 21199649

Publications 2010

Vik-Mo EO, Reinlie S, Helseth E, Langmoen IA (2010)
Neurosurgery in Oslo
World Neurosurg, 74 (4-5), 402-6
DOI 10.1016/j.wneu.2010.10.029, PubMed 21492578

Vik-Mo EO, Sandberg C, Olstorn H, Varghese M, Brandal P, Ramm-Pettersen J, Murrell W, Langmoen IA (2010)
Brain tumor stem cells maintain overall phenotype and tumorigenicity after in vitro culturing in serum-free conditions
Neuro Oncol, 12 (12), 1220-30
DOI 10.1093/neuonc/noq102, PubMed 20843775

Publications 2008

Moe MC, Kolberg RS, Sandberg C, Vik-Mo E, Olstorn H, Varghese M, Langmoen IA, Nicolaissen B (2008)
A comparison of epithelial and neural properties in progenitor cells derived from the adult human ciliary body and brain
Exp Eye Res, 88 (1), 30-8
DOI 10.1016/j.exer.2008.09.020, PubMed 18955049

Varghese M, Olstorn H, Sandberg C, Vik-Mo EO, Noordhuis P, Nistér M, Berg-Johnsen J, Moe MC, Langmoen IA (2008)
A comparison between stem cells from the adult human brain and from brain tumors
Neurosurgery, 63 (6), 1022-33; discussion 1033-4
DOI 10.1227/01.NEU.0000335792.85142.B0, PubMed 19057315

Vik-Mo EO, Øksnes M, Pedersen PH, Wentzel-Larsen T, Rødahl E, Thorsen F, Schreiner T, Aanderud S, Lund-Johansen M (2008)
Gamma knife stereotactic radiosurgery of Nelson syndrome
Eur J Endocrinol, 160 (2), 143-8
DOI 10.1530/EJE-08-0687, PubMed 18996962

Publications 2007

Farbu E, Rekand T, Vik-Mo E, Lygren H, Gilhus NE, Aarli JA (2007)
Post-polio syndrome patients treated with intravenous immunoglobulin: a double-blinded randomized controlled pilot study
Eur J Neurol, 14 (1), 60-5
DOI 10.1111/j.1468-1331.2006.01552.x, PubMed 17222115

Vik-Mo EO, Oksnes M, Pedersen PH, Wentzel-Larsen T, Rødahl E, Thorsen F, Schreiner T, Aanderud S, Lund-Johansen M (2007)
Gamma knife stereotactic radiosurgery for acromegaly
Eur J Endocrinol, 157 (3), 255-63
DOI 10.1530/EJE-07-0189, PubMed 17766706

Publications 2003

Hasegawa H, Zinsser S, Rhee Y, Vik-Mo EO, Davanger S, Hay JC (2003)
Mammalian ykt6 is a neuronal SNARE targeted to a specialized compartment by its profilin-like amino terminal domain
Mol Biol Cell, 14 (2), 698-720
DOI 10.1091/mbc.e02-09-0556, PubMed 12589064

Vik-Mo EO, Oltedal L, Hoivik EA, Kleivdal H, Eidet J, Davanger S (2003)
Sec6 is localized to the plasma membrane of mature synaptic terminals and is transported with secretogranin II-containing vesicles
Neuroscience, 119 (1), 73-85
DOI 10.1016/s0306-4522(03)00065-4, PubMed 12763070

Publications 1999

Tsujimoto S, Pelto-Huikko M, Aitola M, Meister B, Vik-Mo EO, Davanger S, Scheller RH, Bean AJ (1999)
The cellular and developmental expression of hrs-2 in rat
Eur J Neurosci, 11 (9), 3047-63
DOI 10.1046/j.1460-9568.1999.00716.x, PubMed 10510169

Scroll to top